ESPITE advances in medical and surgical therapy for patients with aneurysmal SAH, cerebral vasospasm remains a major complication and contributes to death and disability. The current standard treatment for SAH is triple-H therapy and administration of a Ca ϩϩ channel blocker (for example, nimodipine) in conjunction with early surgical or endovascular intervention. In combination with nimodipine, triple-H therapy has shown results superior to those of triple-H therapy alone. 13, 44 This regimen has reduced mortality rates after aneurysmal SAH to approximately 5 to 15%, compared with almost 20% in the early 1980s.
of an ongoing SAH database for a National Institutes of Health-funded study (R01NR04339). The sample included adult patients (age range 18-75 years) in whom a diagnosis of SAH from a ruptured cerebral aneurysm had been verified by DS angiography or CT angiography and in whom the Hunt and Hess grade was greater than or equal to II and/or the Fisher grade was less than 1. Patients were admitted to the neurovascular intensive care unit at the University of Pittsburgh Medical Center between July 6, 1999, and June 30, 2004 . Informed consent was obtained on the basis of an institutional review board-accepted protocol. All patients received standard nursing and medical care, including triple-H therapy, nimodipine, and early (within 24 hours) surgical or endovascular intervention. Patients were excluded from the parent study if they had a preexisting neurological disorder, if their SAH resulted from a mycotic aneurysm or trauma, or if they presented more than 48 hours after the initial aneurysmal SAH. Cardiomyopathy and electrocardiography changes on admission also constituted exclusion criteria because of the negative cardiac side effects of high serum Mg levels.
Magnesium Sulfate Infusion
Magnesium sulfate infusions were initiated as the standard of care after verification of the presence of SAH from a ruptured aneurysm. Each day, 12 g of MgSO 4 in 500 ml of 0.9% NaCl was given intravenously at a rate of 21 ml/hour. The target infusion duration was 12 days. All medications administered during the hospital course were reviewed using electronic medical records. Nursing and pharmacy notes were analyzed for verification of MgSO 4 infusion and detection of any adverse events. In patients receiving continuous MgSO 4 infusion, measurement of Mg ϩϩ levels was part of the daily standard serological studies. In the historical control patients, serum Mg ϩϩ levels were obtained less frequently, but at least one serum Mg ϩϩ level was available.
Cerebral Vasospasm
Cerebral vasospasm was diagnosed by the documentation of narrowed cerebral vessels on cerebral angiography (DS angiography [ Fig. 1 ] or CT angiography) or TCD ultrasonography-measured elevations when accompanied by a blood flow study such as CT perfusion. 37, 43 Cerebral angiography or CT angiography was conducted as the standard of care on admission, at follow up, or in the event of any neurological deterioration. The angiographic studies were interpreted and graded by neuroradiologists and neurosurgeons at the University of Pittsburgh Medical Center for evidence and degree of vasospasm. The degree of vasospasm was defined as the percentage of cerebral vessel narrowing, as follows: none to minimal, 0 to 25%; moderate, 26 to 75%; and severe, 76 to 99%. In cases involving either moderate or severe vasospasm, findings were classified as positive for cerebral vasospasm.
Each patient underwent TCD ultrasonography daily, from the time of consent in the parent study through the 14th day after onset of hemorrhage, unless he or she was discharged early from the acute inpatient setting. An MCA systolic velocity greater than 200 cm/second, a mean velocity greater than 120 cm/second, or a Lindegaard ratio (ratio of the mean MCA velocity to mean internal carotid artery velocity) greater than 2.5 was coded as indicating a high risk of vasospasm. 29 Patients were monitored for signs of neurological deterioration every 2 to 4 hours for up to 14 days after the aneurysmal rupture. Criteria for determining neurological deterioration included a decline of more than two points on the Glasgow Coma Scale or the National Institutes of Health Stroke Scale and/or documented focal or global neurological change.
Symptomatic vasospasm was defined as neurological deterioration accompanied by CT angiography-or DS angiography-documented vasospasm, or neurological deterioration accompanied by elevated TCD velocities and lowflow CT perfusion scans.
Treatment Outcomes
Outcomes were evaluated by means of telephone conversations or face-to-face meetings, using a battery composed of the GOS, mRS, BI, and the Physical Function subscale of the SF-36. Patients participated in the telephone interview if able; otherwise, a family member or caregiver responded to the questions.
Statistical Analysis
Descriptive statistics, analysis of variance, and chi-square analysis were conducted using SPSS software (version 11.0.1; SPSS, Inc., Chicago, IL), with alpha levels set at 0.05. The chi-square test was used to determine the association between GOS scores, mRS scores, and the presence/ absence of MgSO 4 infusion. Analysis of variance was used to determine differences in BI and SF-36 scores between the groups. Outcome was dichotomized into poor (mRS Score 2-6; GOS Score 1-4) and good (mRS Score 0 or 1; GOS Score 5). The association between poor outcome and MgSO 4 infusion was examined using the chi-square test. Mean values are presented Ϯ standard deviations. Table 1 summarizes the characteristics of the 76 patients included in this study. Thirty-eight patients who received continuous MgSO 4 infusion were identically matched for age, race, and sex with 38 patients in the control group who did not receive this therapy, and closely matched on severity of hemorrhage and treatment intervention (endovascular coil embolization or craniotomy with clip placement). There was no significant difference between the groups with regard to medical history, including smoking. The average time from onset of hemorrhage to admission was 15 Ϯ 23.6 hours (range 1-148.5 hours). The mean patient age was 54.6 years, and the majority (71%) were female. The most common aneurysm sites were the anterior communicating artery ( 
Results

Results of MgSO 4 Infusion
The total infusion duration ranged from 6 to 21 days. In-fusions were standardized regardless of the initial serum Mg ϩϩ levels. Baseline serum Mg ϩϩ levels were higher in the MgSO 4 infusion group; however, in some cases Mg ϩϩ levels may have been measured after the initiation of MgSO 4 infusion ( Table 2 ). The patients who received infusions for fewer than 10 days either were discharged early from the inpatient setting or suffered terminal events such as withdrawal of medical therapy or brain death. One patient underwent MgSO 4 therapy for 21 days. Because this patient experienced persistent problems with vasospasm, the MgSO 4 therapy was continued beyond Day 12. No adverse events that would have led to discontinuation of MgSO 4 therapy were detected. Serological studies were performed to monitor MgSO 4 levels. Serum Mg ϩϩ levels ranged from 0.9 to 5.2 mmol/L (mean 2.16 Ϯ 0.38 mmol/L) in the MgSO 4 -treated group, compared with 1.1 to 3.8 mmol/L (mean 1.17 mmol/L) in the control group, a difference that was statistically significant (p Յ 0.0001; Table 2 ).
Magnesium Sulfate and Symptomatic Cerebral Vasospasm
There was a significant difference in the incidence of symptomatic cerebral vasospasm in patients who received the MgSO 4 infusions compared with control patients (Fig.  2) . Symptomatic cerebral vasospasm was present in 23 (30%) of the 76 patients with cerebral vasospasm. Based on DS angiography findings and evidence of neurological deterioration, we found that symptomatic cerebral vasospasm was present in seven (18.4%) of 38 patients who received MgSO 4 infusion. In contrast, symptoms were present in 16 (42%) of 38 control patients ( 2 = 5.05, p = 0.025; OR 1.99, 95% CI 0.99-3.7). In two control patients who did not undergo angiography or CT angiography, the presence of cerebral vasospasm was indicated by TCD ultrasonography-measured elevated velocities, neurological changes, and low-flow CT perfusion scans.
Magnesium Sulfate and 3-Month Outcomes
There was no significant difference in mortality rate between the MgSO 4 -treated group and the control group. By 3 months, four patients (10.5%) in the MgSO 4 -treated group had died, whereas seven (18%) in the control group had died ( 2 = 0.957, p = 0.328; OR 1.7, 95% CI 0.56-5.5). The mean mRS score was 2.22 Ϯ 1.943 for the entire group-2 for the MgSO 4 group and 2.45 for the control group. When the data were dichotomized into good (mRS Score 1) and poor (mRS Score Ͼ 1) outcomes, the OR was 2.1 ( 2 = 0.168, p = 0.084; 95% CI 0.84-5.27). The mean GOS score was 3.84 Ϯ 1.35 for the entire group-3.89 for the MgSO 4 group and 3.79 for the control group. There was no significant intergroup difference in outcomes when the data were dichotomized into good (GOS Score 5) and poor (GOS Score 1-4) outcomes ( 2 = 0.00, p = 1.0; OR 1, 95% CI 0.4-2.49).
There was no significant difference in BI scores between groups (p = 0.84). The mean BI score was 17.3 Ϯ 5.5 in the MgSO 4 -infused group and 17.5 Ϯ 5.3 in the control group. At the 3-month follow up, the mean SF-36 Physical Function score in the overall sample was 19.4 Ϯ 6 (range 9-27). The mean SF-36 Physical Function score in the MgSO 4 group was 24.3 Ϯ 17.7, whereas that in the control group was 28.4 Ϯ 19.8. This difference was not significant (p = 0.34).
Discussion
In this study, we have demonstrated that prophylactic continuous MgSO 4 infusion after SAH is beneficial and safe. Infusion of MgSO 4 decreased the incidence of cerebral vasospasm and resulted in a trend toward improved clinical outcome. Magnesium is thought to ameliorate cerebral vasospasm by many mechanisms: vasodilation, inhibition of free radical formation, impedance of vasoconstrictive substances, and inhibition of platelet aggregation. It may also be beneficial to patients with cerebral vasospasm because of its neuroprotective properties. 27, 50 and most recently, recombinant human erythropoietin. 11 Whereas these treatments work on one specific pathophysiological mechanism involved in the genesis of cerebral vasospasm, MgSO 4 counteracts various pathways and spasmogenic substances, such as endothelin-1, 23 norepinephrine, angiotensin II, 2 and serotonin. 45 This could contribute further to the vasodilatory effect. 1-3.8) (1.1-2.0) (1.3-3.8) (1.3-2 Magnesium is not only a vasodilator; it also has shown an antiplatelet effect in clinical studies. 42 Thromboxane and serotonins released from platelets during platelet aggregation in the subarachnoid clot are suspected to contribute to vasospasm. 39 This process is reflected in the correlation of Fisher grade with vasospasm severity 38 and the reduced risk of cerebral vasospasm brought about by the removal of blood products from the subarachnoid space via cisternal drainage. 18, 22, 24 In a rabbit model of cerebrovascular injury, 26 as well as in healthy human volunteers, 42 high serum concentrations of Mg ϩϩ were associated with inhibited platelet aggregation and prolonged bleeding time. No hemorrhagerelated complications were reported in several large clinical trials of Mg ϩϩ in patients with myocardial infarction, 16, 31 even in combination with antiplatelet agents and thrombolytic drugs. 3 Increased blood loss was reported, however, in women who received MgSO 4 for the treatment of preeclampsia. 28 In contrast, the authors of a study of patients with SAH who received similarly high Mg ϩϩ doses did not report any bleeding-related complications. 47 In the present study, we did not observe any hemorrhage-related complications or other adverse effects as a result of MgSO 4 administration.
Effect of MgSO 4 on Cerebral Vasospasm
Magnesium for Prevention of Cerebral Vasospasm
Several studies have been performed to establish the efficacy of MgSO 4 in cerebral vasospasm prevention. In these studies, MgSO 4 was administered in accordance with different protocols, which could account for the variety of results. Whereas the authors of one study in which mean serum Mg ϩϩ levels were in the 1 to 1.5-mmol/L range found significant reduction of radiographically documented vasospasm, 10 the authors of another study in which serum Mg ϩϩ levels were maintained in the 2-to 2.5-mmol/L range did not observe any benefit. 6 Additionally, high-dose MgSO 4 infusion, resulting in a serum Mg ϩϩ level as high as 4 to 4.5 mg/dl (3.3-3.7 mmol/L), did not alter vasospasm or improve outcome significantly. 47 Administration of a single bolus of MgSO 4 produced similar results. 7 It seems that the MgSO 4 bolus has a predominantly vasodilatory effect on systemic vasculature but no detectable effect on intracranial circulation. An intravenous MgSO 4 bolus immediately elevates serum Mg ϩϩ levels but may take hours to affect CSF levels. 15 In the present study, a continuous infusion of Mg ϩϩ was started prophylactically within 48 hours after aneurysm rupture was verified. Consequently, there was sufficient time for tissue loading before the onset of cerebral vasospasm. This emphasizes the importance of administration of MgSO 4 continuously and as early as possible after aneurysm rupture to prevent cerebral vasospasm. In addition, if MgSO 4 therapy is not initiated before the onset of vasospasm, vasoparalysis may abolish the vasodilatory effect of magnesium in cerebral arteries. 7 Although the neuroprotective properties of a serum Mg ϩϩ concentration of 1.49 mmol/L have been established in patients with stroke, 35 the proper concentration needed to achieve a vasodilatory response in the intracranial circulation is unclear. Analysis of data obtained in primates shows that the concentration of MgSO 4 in CSF increases simultaneously with the concentration of Mg ϩϩ in serum, but to a lesser extent. 30 The goal of future studies should be to establish in vivo vasoactive concentrations in both serum and CSF.
Neuroprotective Effects of MgSO 4
In addition to its vasodilatory effect, MgSO 4 is thought to exert a neuroprotective effect. This neuroprotective effect was first established in animal models of traumatic brain injury. 33 In the most recent clinical trials involving patients with acute stroke, a neuroprotective effect could be seen only in a small subgroup. 34, 36 For example, in the Intravenous Magnesium Efficacy for Stroke study, a much smaller dose (16 mmol or 2 g) of MgSO 4 was used. In addition, because MgSO 4 cannot be given prophylactically to treat acute stroke, its neuroprotective property might be diminished in that clinical setting. Magnesium is able to impede neuronal death via multiple pathways. It disrupts the excitotoxic cascade by competitive antagonism at the N-methyl-D-aspartate receptor. 14, 21 Moreover, MgSO 4 inhibits glutamate release by enhancing the effect of adenosine on the magnesium-dependent presynaptic adenosine-1 receptors, further diminishing excitatory glutamate neurotoxicity. 4 Magnesium affects O 2 radical formation, one of the major pathways contributing to vasospasm. 12, 16, 48 It inhibits nicotinamide-adenine dinucleotide phosphate oxidase, an enzyme that produces the superoxide radical. 1 Magnesium also alters postanoxic depolarization. Depolarization induces an ion shift that contributes to energy failure, cerebral ischemia, and cell death in the ischemic brain. Van den Bergh, et al., 46 recorded ischemic depolarization potentials for as long as 90 minutes after SAH. They used diffusion-weighted magnetic resonance imaging to measure the volume of ischemic tissue. Significantly less ischemic brain tissue was found in rats pretreated with intravenous Mg ϩϩ . This finding has led researchers to suggest that Mg ϩϩ provides a measure of neuroprotection, even in the presence of cerebral vasospasm, and could explain the trend toward better neurological outcomes in patients treated with magnesium.
Conclusions
The findings of this study lead us to suggest that continuous MgSO 4 infusion is safe and may play a role in the prophylaxis of cerebral vasospasm. We found a significant reduction in vasospasm and a trend toward improved outcome when continuous MgSO 4 therapy was initiated within 48 hours after aneurysm rupture. This study did not have sufficient power to show a statistically significant difference in outcome, but the evidence derived herein provides support for a large-scale randomized clinical trial in which the Mg ϩϩ dose is titrated to gain the maximum vasodilatory and neuroprotective effects. It may also be essential to administer MgSO 4 prophylactically and continuously, so that tissue binding and transport across the blood-brain barrier occur before the onset of cerebral vasospasm.
